Compile Data Set for Download or QSAR
Report error Found 58 Enz. Inhib. hit(s) with all data for entry = 13512
TargetProtein-tyrosine kinase 2-beta(Human)
Samjin Pharmaceutical Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 801010BDBM801010(adamantan-1-carboxamide | US12590070, Compound 30)
Affinity DataIC50: 18.2nMAssay Description:The inhibitory activity of the adamantane derivative compounds of the present invention to FAK, Pyk2 and InsR was confirmed through a biochemical kin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/10/2026
Entry Details
US Patent

TargetFocal adhesion kinase 1(Human)
Samjin Pharmaceutical Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 801009BDBM801009(adamantan-1-carboxamide | US12590070, Compound 28)
Affinity DataIC50: 29nMAssay Description:The inhibitory activity of the adamantane derivative compounds of the present invention to FAK, Pyk2 and InsR was confirmed through a biochemical kin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/10/2026
Entry Details
US Patent

TargetFocal adhesion kinase 1(Human)
Samjin Pharmaceutical Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 801008BDBM801008(adamantan-1-carboxamide | US12590070, Compound 27)
Affinity DataIC50: 39.5nMAssay Description:The inhibitory activity of the adamantane derivative compounds of the present invention to FAK, Pyk2 and InsR was confirmed through a biochemical kin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/10/2026
Entry Details
US Patent

TargetFocal adhesion kinase 1(Human)
Samjin Pharmaceutical Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 801016BDBM801016(adamantan-1-carboxylate | US12590070, Compound 37)
Affinity DataIC50: 43.6nMAssay Description:The inhibitory activity of the adamantane derivative compounds of the present invention to FAK, Pyk2 and InsR was confirmed through a biochemical kin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/10/2026
Entry Details
US Patent

TargetFocal adhesion kinase 1(Human)
Samjin Pharmaceutical Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 801007BDBM801007(N-(3-methoxy-4-((4-((2-methyl-6-(methylcarbamoyl)p...)
Affinity DataIC50: 45.5nMAssay Description:The inhibitory activity of the adamantane derivative compounds of the present invention to FAK, Pyk2 and InsR was confirmed through a biochemical kin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/10/2026
Entry Details
US Patent

TargetFocal adhesion kinase 1(Human)
Samjin Pharmaceutical Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 800993BDBM800993(2-((2-((4-(4-((trans)-5-hydroxyadamantan-2-yl)pipe...)
Affinity DataIC50: 46.2nMAssay Description:The inhibitory activity of the adamantane derivative compounds of the present invention to FAK, Pyk2 and InsR was confirmed through a biochemical kin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/10/2026
Entry Details
US Patent

TargetFocal adhesion kinase 1(Human)
Samjin Pharmaceutical Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 800996BDBM800996(2-((2-((4-((1-((trans)-5-hydroxyadamantan-2-yl)pip...)
Affinity DataIC50: 46.9nMAssay Description:The inhibitory activity of the adamantane derivative compounds of the present invention to FAK, Pyk2 and InsR was confirmed through a biochemical kin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/10/2026
Entry Details
US Patent

TargetFocal adhesion kinase 1(Human)
Samjin Pharmaceutical Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 800997BDBM800997(2-((2-((4-((1-((cis)-5-hydroxyadamantan-2-yl)piper...)
Affinity DataIC50: 53.3nMAssay Description:The inhibitory activity of the adamantane derivative compounds of the present invention to FAK, Pyk2 and InsR was confirmed through a biochemical kin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/10/2026
Entry Details
US Patent

TargetFocal adhesion kinase 1(Human)
Samjin Pharmaceutical Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 801005BDBM801005(adamantan-2-yl)amino)phenyl)amino)-5-(trifluoromet...)
Affinity DataIC50: 57nMAssay Description:The inhibitory activity of the adamantane derivative compounds of the present invention to FAK, Pyk2 and InsR was confirmed through a biochemical kin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/10/2026
Entry Details
US Patent

TargetFocal adhesion kinase 1(Human)
Samjin Pharmaceutical Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 801001BDBM801001(adamantan-1-yl)oxy)-2-methoxyphenyl)amino)-5-(trif...)
Affinity DataIC50: 57nMAssay Description:The inhibitory activity of the adamantane derivative compounds of the present invention to FAK, Pyk2 and InsR was confirmed through a biochemical kin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/10/2026
Entry Details
US Patent

TargetFocal adhesion kinase 1(Human)
Samjin Pharmaceutical Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 801018BDBM801018(acid | US12590070, Compound 39)
Affinity DataIC50: 58nMAssay Description:The inhibitory activity of the adamantane derivative compounds of the present invention to FAK, Pyk2 and InsR was confirmed through a biochemical kin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/10/2026
Entry Details
US Patent

TargetFocal adhesion kinase 1(Human)
Samjin Pharmaceutical Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 801019BDBM801019(acid | US12590070, Compound 40)
Affinity DataIC50: 58.3nMAssay Description:The inhibitory activity of the adamantane derivative compounds of the present invention to FAK, Pyk2 and InsR was confirmed through a biochemical kin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/10/2026
Entry Details
US Patent

TargetFocal adhesion kinase 1(Human)
Samjin Pharmaceutical Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 801015BDBM801015(2-((5-chloro-2-((4-(4-((trans)-5-hydroxyadamantan-...)
Affinity DataIC50: 61.4nMAssay Description:The inhibitory activity of the adamantane derivative compounds of the present invention to FAK, Pyk2 and InsR was confirmed through a biochemical kin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/10/2026
Entry Details
US Patent

TargetProtein-tyrosine kinase 2-beta(Human)
Samjin Pharmaceutical Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 801009BDBM801009(adamantan-1-carboxamide | US12590070, Compound 28)
Affinity DataIC50: 64.5nMAssay Description:The inhibitory activity of the adamantane derivative compounds of the present invention to FAK, Pyk2 and InsR was confirmed through a biochemical kin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/10/2026
Entry Details
US Patent

TargetFocal adhesion kinase 1(Human)
Samjin Pharmaceutical Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 801000BDBM801000(US12590070, Compound 11)
Affinity DataIC50: 65.1nMAssay Description:The inhibitory activity of the adamantane derivative compounds of the present invention to FAK, Pyk2 and InsR was confirmed through a biochemical kin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/10/2026
Entry Details
US Patent

TargetFocal adhesion kinase 1(Human)
Samjin Pharmaceutical Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 800994BDBM800994(2-((2-((4-(4-((cis)-5-hydroxyadamantan-2-yl)pipera...)
Affinity DataIC50: 69.9nMAssay Description:The inhibitory activity of the adamantane derivative compounds of the present invention to FAK, Pyk2 and InsR was confirmed through a biochemical kin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/10/2026
Entry Details
US Patent

TargetFocal adhesion kinase 1(Human)
Samjin Pharmaceutical Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 801017BDBM801017(adamantan-1-carboxylate | US12590070, Compound 38)
Affinity DataIC50: 70nMAssay Description:The inhibitory activity of the adamantane derivative compounds of the present invention to FAK, Pyk2 and InsR was confirmed through a biochemical kin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/10/2026
Entry Details
US Patent

TargetFocal adhesion kinase 1(Human)
Samjin Pharmaceutical Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 801006BDBM801006(adamantan-2-yl)amino)phenyl)amino)-5-(trifluoromet...)
Affinity DataIC50: 77.5nMAssay Description:The inhibitory activity of the adamantane derivative compounds of the present invention to FAK, Pyk2 and InsR was confirmed through a biochemical kin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/10/2026
Entry Details
US Patent

TargetProtein-tyrosine kinase 2-beta(Human)
Samjin Pharmaceutical Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 801008BDBM801008(adamantan-1-carboxamide | US12590070, Compound 27)
Affinity DataIC50: 81.4nMAssay Description:The inhibitory activity of the adamantane derivative compounds of the present invention to FAK, Pyk2 and InsR was confirmed through a biochemical kin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/10/2026
Entry Details
US Patent

TargetFocal adhesion kinase 1(Human)
Samjin Pharmaceutical Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 800990BDBM800990(US12590070, Compound 1)
Affinity DataIC50: 82.9nMAssay Description:The inhibitory activity of the adamantane derivative compounds of the present invention to FAK, Pyk2 and InsR was confirmed through a biochemical kin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/10/2026
Entry Details
US Patent

TargetProtein-tyrosine kinase 2-beta(Human)
Samjin Pharmaceutical Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 801007BDBM801007(N-(3-methoxy-4-((4-((2-methyl-6-(methylcarbamoyl)p...)
Affinity DataIC50: 90.6nMAssay Description:The inhibitory activity of the adamantane derivative compounds of the present invention to FAK, Pyk2 and InsR was confirmed through a biochemical kin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/10/2026
Entry Details
US Patent

TargetFocal adhesion kinase 1(Human)
Samjin Pharmaceutical Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 801002BDBM801002(4-(3-methoxy-4-((4-((2-methyl-6-(methylcarbamoyl)p...)
Affinity DataIC50: 92.9nMAssay Description:The inhibitory activity of the adamantane derivative compounds of the present invention to FAK, Pyk2 and InsR was confirmed through a biochemical kin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/10/2026
Entry Details
US Patent

TargetFocal adhesion kinase 1(Human)
Samjin Pharmaceutical Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 800995BDBM800995(2-((2-((4-((1-(adamantan-2-yl)piperidin-4-yl)amino...)
Affinity DataIC50: 96.5nMAssay Description:The inhibitory activity of the adamantane derivative compounds of the present invention to FAK, Pyk2 and InsR was confirmed through a biochemical kin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/10/2026
Entry Details
US Patent

TargetFocal adhesion kinase 1(Human)
Samjin Pharmaceutical Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 800999BDBM800999(US12590070, Compound 10)
Affinity DataIC50: 96.7nMAssay Description:The inhibitory activity of the adamantane derivative compounds of the present invention to FAK, Pyk2 and InsR was confirmed through a biochemical kin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/10/2026
Entry Details
US Patent

TargetFocal adhesion kinase 1(Human)
Samjin Pharmaceutical Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 800998BDBM800998(2-((2-((4-((1-(adamantan-2-yl)piperidin-4-yl)oxy)-...)
Affinity DataIC50: 98.1nMAssay Description:The inhibitory activity of the adamantane derivative compounds of the present invention to FAK, Pyk2 and InsR was confirmed through a biochemical kin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/10/2026
Entry Details
US Patent

TargetFocal adhesion kinase 1(Human)
Samjin Pharmaceutical Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 801004BDBM801004(adamantan-2-yl)oxy)phenyl)amino)-5-(trifluoromethy...)
Affinity DataIC50: 98.9nMAssay Description:The inhibitory activity of the adamantane derivative compounds of the present invention to FAK, Pyk2 and InsR was confirmed through a biochemical kin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/10/2026
Entry Details
US Patent

TargetProtein-tyrosine kinase 2-beta(Human)
Samjin Pharmaceutical Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 801012BDBM801012(2-((2-((4-(1-((cis)-5-hydroxyadamantan-2-yl)piperi...)
Affinity DataIC50: 101nMAssay Description:The inhibitory activity of the adamantane derivative compounds of the present invention to FAK, Pyk2 and InsR was confirmed through a biochemical kin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/10/2026
Entry Details
US Patent

TargetProtein-tyrosine kinase 2-beta(Human)
Samjin Pharmaceutical Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 800996BDBM800996(2-((2-((4-((1-((trans)-5-hydroxyadamantan-2-yl)pip...)
Affinity DataIC50: 108nMAssay Description:The inhibitory activity of the adamantane derivative compounds of the present invention to FAK, Pyk2 and InsR was confirmed through a biochemical kin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/10/2026
Entry Details
US Patent

TargetProtein-tyrosine kinase 2-beta(Human)
Samjin Pharmaceutical Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 800990BDBM800990(US12590070, Compound 1)
Affinity DataIC50: 124nMAssay Description:The inhibitory activity of the adamantane derivative compounds of the present invention to FAK, Pyk2 and InsR was confirmed through a biochemical kin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/10/2026
Entry Details
US Patent

TargetFocal adhesion kinase 1(Human)
Samjin Pharmaceutical Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 801003BDBM801003(adamantan-2-yl)oxy)phenyl)amino)-5-(trifluoromethy...)
Affinity DataIC50: 127nMAssay Description:The inhibitory activity of the adamantane derivative compounds of the present invention to FAK, Pyk2 and InsR was confirmed through a biochemical kin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/10/2026
Entry Details
US Patent

TargetProtein-tyrosine kinase 2-beta(Human)
Samjin Pharmaceutical Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 800993BDBM800993(2-((2-((4-(4-((trans)-5-hydroxyadamantan-2-yl)pipe...)
Affinity DataIC50: 150nMAssay Description:The inhibitory activity of the adamantane derivative compounds of the present invention to FAK, Pyk2 and InsR was confirmed through a biochemical kin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/10/2026
Entry Details
US Patent

TargetFocal adhesion kinase 1(Human)
Samjin Pharmaceutical Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 800992BDBM800992(2-((2-((4-(4-(adamantan-2-yl)piperazin-1-yl)-2-met...)
Affinity DataIC50: 154nMAssay Description:The inhibitory activity of the adamantane derivative compounds of the present invention to FAK, Pyk2 and InsR was confirmed through a biochemical kin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/10/2026
Entry Details
US Patent

TargetProtein-tyrosine kinase 2-beta(Human)
Samjin Pharmaceutical Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 801011BDBM801011(2-((2-((4-(1-((trans)-5-hydroxyadamantan-2-yl)pipe...)
Affinity DataIC50: 154nMAssay Description:The inhibitory activity of the adamantane derivative compounds of the present invention to FAK, Pyk2 and InsR was confirmed through a biochemical kin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/10/2026
Entry Details
US Patent

TargetProtein-tyrosine kinase 2-beta(Human)
Samjin Pharmaceutical Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 800995BDBM800995(2-((2-((4-((1-(adamantan-2-yl)piperidin-4-yl)amino...)
Affinity DataIC50: 157nMAssay Description:The inhibitory activity of the adamantane derivative compounds of the present invention to FAK, Pyk2 and InsR was confirmed through a biochemical kin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/10/2026
Entry Details
US Patent

TargetFocal adhesion kinase 1(Human)
Samjin Pharmaceutical Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 800991BDBM800991(2-((2-((4-(adamantan-2-ylamino)-2-methoxyphenyl)am...)
Affinity DataIC50: 206nMAssay Description:The inhibitory activity of the adamantane derivative compounds of the present invention to FAK, Pyk2 and InsR was confirmed through a biochemical kin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/10/2026
Entry Details
US Patent

TargetProtein-tyrosine kinase 2-beta(Human)
Samjin Pharmaceutical Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 801000BDBM801000(US12590070, Compound 11)
Affinity DataIC50: 231nMAssay Description:The inhibitory activity of the adamantane derivative compounds of the present invention to FAK, Pyk2 and InsR was confirmed through a biochemical kin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/10/2026
Entry Details
US Patent

TargetProtein-tyrosine kinase 2-beta(Human)
Samjin Pharmaceutical Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 800992BDBM800992(2-((2-((4-(4-(adamantan-2-yl)piperazin-1-yl)-2-met...)
Affinity DataIC50: 256nMAssay Description:The inhibitory activity of the adamantane derivative compounds of the present invention to FAK, Pyk2 and InsR was confirmed through a biochemical kin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/10/2026
Entry Details
US Patent

TargetProtein-tyrosine kinase 2-beta(Human)
Samjin Pharmaceutical Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 801014BDBM801014(2-((2-((4-(1-((cis)-5-hydroxyadamantan-2-yl)piperi...)
Affinity DataIC50: 418nMAssay Description:The inhibitory activity of the adamantane derivative compounds of the present invention to FAK, Pyk2 and InsR was confirmed through a biochemical kin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/10/2026
Entry Details
US Patent

TargetProtein-tyrosine kinase 2-beta(Human)
Samjin Pharmaceutical Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 801013BDBM801013(2-((2-((4-(1-((trans)-5-hydroxyadamantan-2-yl)pipe...)
Affinity DataIC50: 427nMAssay Description:The inhibitory activity of the adamantane derivative compounds of the present invention to FAK, Pyk2 and InsR was confirmed through a biochemical kin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/10/2026
Entry Details
US Patent

TargetInsulin receptor(Human)
Samjin Pharmaceutical Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 801014BDBM801014(2-((2-((4-(1-((cis)-5-hydroxyadamantan-2-yl)piperi...)
Affinity DataIC50: 1.44E+3nMAssay Description:The inhibitory activity of the adamantane derivative compounds of the present invention to FAK, Pyk2 and InsR was confirmed through a biochemical kin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/10/2026
Entry Details
US Patent

TargetInsulin receptor(Human)
Samjin Pharmaceutical Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 801013BDBM801013(2-((2-((4-(1-((trans)-5-hydroxyadamantan-2-yl)pipe...)
Affinity DataIC50: 1.64E+3nMAssay Description:The inhibitory activity of the adamantane derivative compounds of the present invention to FAK, Pyk2 and InsR was confirmed through a biochemical kin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/10/2026
Entry Details
US Patent

TargetInsulin receptor(Human)
Samjin Pharmaceutical Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 801012BDBM801012(2-((2-((4-(1-((cis)-5-hydroxyadamantan-2-yl)piperi...)
Affinity DataIC50: 2.05E+3nMAssay Description:The inhibitory activity of the adamantane derivative compounds of the present invention to FAK, Pyk2 and InsR was confirmed through a biochemical kin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/10/2026
Entry Details
US Patent

TargetInsulin receptor(Human)
Samjin Pharmaceutical Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 801011BDBM801011(2-((2-((4-(1-((trans)-5-hydroxyadamantan-2-yl)pipe...)
Affinity DataIC50: 2.15E+3nMAssay Description:The inhibitory activity of the adamantane derivative compounds of the present invention to FAK, Pyk2 and InsR was confirmed through a biochemical kin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/10/2026
Entry Details
US Patent

TargetInsulin receptor(Human)
Samjin Pharmaceutical Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 801010BDBM801010(adamantan-1-carboxamide | US12590070, Compound 30)
Affinity DataIC50: 3.80E+3nMAssay Description:The inhibitory activity of the adamantane derivative compounds of the present invention to FAK, Pyk2 and InsR was confirmed through a biochemical kin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/10/2026
Entry Details
US Patent

TargetInsulin receptor(Human)
Samjin Pharmaceutical Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 800994BDBM800994(2-((2-((4-(4-((cis)-5-hydroxyadamantan-2-yl)pipera...)
Affinity DataIC50: 4.69E+3nMAssay Description:The inhibitory activity of the adamantane derivative compounds of the present invention to FAK, Pyk2 and InsR was confirmed through a biochemical kin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/10/2026
Entry Details
US Patent

TargetInsulin receptor(Human)
Samjin Pharmaceutical Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 800993BDBM800993(2-((2-((4-(4-((trans)-5-hydroxyadamantan-2-yl)pipe...)
Affinity DataIC50: 5.67E+3nMAssay Description:The inhibitory activity of the adamantane derivative compounds of the present invention to FAK, Pyk2 and InsR was confirmed through a biochemical kin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/10/2026
Entry Details
US Patent

TargetInsulin receptor(Human)
Samjin Pharmaceutical Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 800996BDBM800996(2-((2-((4-((1-((trans)-5-hydroxyadamantan-2-yl)pip...)
Affinity DataIC50: 6.15E+3nMAssay Description:The inhibitory activity of the adamantane derivative compounds of the present invention to FAK, Pyk2 and InsR was confirmed through a biochemical kin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/10/2026
Entry Details
US Patent

TargetInsulin receptor(Human)
Samjin Pharmaceutical Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 800995BDBM800995(2-((2-((4-((1-(adamantan-2-yl)piperidin-4-yl)amino...)
Affinity DataIC50: 1.00E+4nMAssay Description:The inhibitory activity of the adamantane derivative compounds of the present invention to FAK, Pyk2 and InsR was confirmed through a biochemical kin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/10/2026
Entry Details
US Patent

TargetInsulin receptor(Human)
Samjin Pharmaceutical Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 800990BDBM800990(US12590070, Compound 1)
Affinity DataIC50: 1.00E+4nMAssay Description:The inhibitory activity of the adamantane derivative compounds of the present invention to FAK, Pyk2 and InsR was confirmed through a biochemical kin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/10/2026
Entry Details
US Patent

TargetInsulin receptor(Human)
Samjin Pharmaceutical Co.

US Patent
LigandChemical structure of BindingDB Monomer ID 800991BDBM800991(2-((2-((4-(adamantan-2-ylamino)-2-methoxyphenyl)am...)
Affinity DataIC50: 1.00E+4nMAssay Description:The inhibitory activity of the adamantane derivative compounds of the present invention to FAK, Pyk2 and InsR was confirmed through a biochemical kin...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/10/2026
Entry Details
US Patent

Displayed 1 to 50 (of 58 total ) | Next | Last >>
Jump to: